One Case of Hepatic Injury Induced by Cefoperazone Sodium/Sulbactam Sodium for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection

Abstract

CLC Number:

R994.11

WEN Zhiyong, LU Wenfen. One Case of Hepatic Injury Induced by Cefoperazone Sodium/Sulbactam Sodium for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 253-254.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I4/253

References

[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1768.
[2] Chalasani N P, Hayashi P H, Bonkovsky H L, et al.ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury[J]. The American Journal of Gastroenterology, 2014, 109(7):950-966.
[3] 江红接. 头孢哌酮舒巴坦钠致急性药物性肝损伤1例[J]. 肝脏,2014,19(1): 11.
[4] 唐莉,赵艳霞. 头孢哌酮舒巴坦钠致重症多形红斑型药疹合并肝损害1例[J]. 中国中西医结合皮肤性病学杂志,2010,9(2):123-124.
[5] 李冬云, 刘国树. 头孢哌酮钠/舒巴坦钠致严重肝功能损害[J]. 药物不良反应杂志, 2003, 5(1):47.
[6] 张斌,王楠,毛敏,等. 氟喹诺酮类药物致肝酶明显升高1例[J]. 中国药物警戒,2016,13(7):437-439.
[7] Nori S, Nebesio C, Brashear R, et al.Moxifloxacin-associated drug hypersensitivity synd- rome with toxic epidermal necrolysis and fulminant hepatic failure[J]. Archives of Dermatology, 2004, 140(12):1537-1538.
[8] 黄丽贞,雷光远,雷招宝. 莫西沙星致肝损害16例文献分析[J]. 药物流行病学杂志,2012,21(12):631-633.
[9] 贾王平,郭代红,田小燕,等. 79家医院1110例药物性肝损害不良反应/事件分析[J]. 中国药物警戒,2017,14(8):481-485.
[10] 徐焕春,乔逸,王婧雯. 注射用头孢哌酮钠/舒巴坦钠和盐酸莫西沙星片致严重肝损害[J]. 中国药物应用与监测,2013,10(2):121-122.
[11] 刘银萍,秦玉花,白楠,等. 莫西沙星在中国健康受试者体内的药代动力学研究[J]. 中国临床药理学杂志,2015,31(13):1255-1257.
[12] 吕晓菊. 注射用头孢哌酮钠/舒巴坦钠(2:1)的研发应用[J]. 中国医院药学杂志,2004,24(7):448.
[13] 何鑫, 刘丽华, 马红玲,等. 药物性肝损伤的临床药学监护[J]. 中国药师,2015,18(12):2107-2109.
[14] 尹小萍, 王辰. 临床药师对抗菌药物致急性药物性肝损伤的药学监护[J]. 中国医院用药评价与分析,2017(10):1434-1436.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.